



Correction to: Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same *MAPT*-P301L mutation

Nathalie Daude¹ · Chae Kim² · Sang-Gyun Kang¹ · Ghazaleh Eskandari-Sedighi^{1,7} · Tracy Haldiman² · Jing Yang¹ · Shelaine C. Fleck^{1,7} · Erik Gomez-Cardona⁷ · Zhuang Zhuang Han^{1,7} · Sergi Borrego-Ecija⁴ · Serene Wohlgemuth¹ · Olivier Julien⁷ · Holger Wille^{1,7} · Laura Molina-Porcel⁵ · Ellen Gelpi^{4,6} · Jiri G. Safar^{2,3} · David Westaway^{1,7}

Published online: 30 January 2021
© Springer-Verlag GmbH Germany, part of Springer Nature 2021

**Correction to: Acta Neuropathologica
(2020) 139:1045–1070
<https://doi.org/10.1007/s00401-020-02148-4>**

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

In the original publication, Table 1 column heads are incorrectly formatted and aligned. The corrected Table 1 is given here.

The original article can be found online at <https://doi.org/10.1007/s00401-020-02148-4>.

✉ Jiri G. Safar
jiri.safar@case.edu

✉ David Westaway
david.westaway@ualberta.ca

¹ Centre for Prions and Protein Folding Diseases, University of Alberta, 204 Brain and Aging Research Building, Edmonton T6G 2M8, Canada

² Department of Pathology, Case Western Reserve University, Institute of Pathology Building, Rm 406, 2085 Adelbert Road, Cleveland, OH 44106-4907, USA

³ Department of Neurology, Case Western Reserve University, Institute of Pathology Building, Rm 406, 2085 Adelbert Road, Cleveland, OH 44106-4907, USA

⁴ Neurological Tissue Bank of the Biobanc, Hospital Clinic, IDIBAPS, Barcelona, Spain

⁵ Neurology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain

⁶ Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria

⁷ Department of Biochemistry, University of Alberta, Edmonton, AB, Canada

Table 1 Clinical and molecular characteristics of ten Iberian FTLD-MAPT-F30IL cases

Case	Sex	Age at death	Duration (years)	Signs at onset	Initial diagnosis	MAPT haplo-type	ApoE	PMI (h)	Frontal cortex	Dentate nucleus of the cerebellum		Hippocampus	Parahippocampus	
										Neuronal loss/AT8	D/N			Neuronal loss/AT8
1	M	52	6	Behavior	bvFTD	H1/H1	e3/e3	13.5	++/+++	3.6±0.2	-/-	1.0±0.0	-/+++	++/+++
2	M	58	5	Behavior	bvFTD	H1/H1	e3/e4	13	+++/>+++	4.1±0.1	-/+	1.0±0.1	-/+++	++/+++
8	M	58	7	Behavior	bvFTD	H1/H1	e3/e4	10	+++/>+++	4.9±0.3	-/+	1.0±0.1	-/+++	+++/>+++
7 ^a	F	61	5	Behavior	bvFTD	H1/H1	e3/e3	14.8	+++/>+++	4.6±0.1	-/+	1.7±0.1	-/+++	+++/>++
4	M	72	13	Memory	AD	H1/H1	e3/e3	5.8	+++/>+++	3.7±0.3	-/+	1.0±0.1	+/>+++	+++/>+++
6	M	53	7	Memory	AD	H1/H1	e3/e3	16.7	+++/>+++	12.6±1.2	-/-	1.2±0.1	-/+++	+++/>+++
9	M	75	7	Behavior	AD	H1/H2	e3/e3	5.9	+++/>+++	5.9±0.1	-/-	3.1±0.1	-/+++	+++/>+++
5	F	63	4	Language	AD or svPPA	H1/H2	e3/e3	7.3	+++/>+++	4.6±0.1	-/+	1.2±0.2	-/+++	+++/>+++
3	M	56	10	Language	svPPA	H1/H1	e3/e3	6.3	+++/>+++	10.3±0.9	-/+	1.0±0.1	-/+++	+++/>+++
12	M	49	6	Language	svPPA	H1/H1	e3/e3	7.4	+++/>+++	8.2±0.5	-/+	3.3±0.1	ND	ND

Table after 34, arranged by initial clinical diagnosis: *BvFTD* behavioral variant of FTD, *svPPA* semantic variant of primary progressive aphasia, *AD* Alzheimer disease, *PMI* post mortem interval. All presented cases were FUS negative, TDP43 negative. *D/N* denatured/native ratio in CDI assay, ± standard deviation

Age at onset was 51.3±4, 60.7±11.9, 50±7 for bv, AD, sv respectively. Age at death was 57.3±3.8, 66.7±11.9 and 56±7 for bv, AD, sv respectively. None of the differences in ages are significant

^aAlso feature globular glial tauopathy affecting oligodendrocytes